Matches in SemOpenAlex for { <https://semopenalex.org/work/W2397805874> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2397805874 endingPage "2" @default.
- W2397805874 startingPage "1" @default.
- W2397805874 abstract "Antiangiogenic therapy has emerged as an important concept in the treatment of solid tumors, including non-small cell lung cancer (NSCLC). Vascular endothelial growth factor (VEGF) represents an important therapeutic target, as it is the primary mediator of angiogenesis and is induced by multiple tumor-relevant stimuli. The anti-VEGF monoclonal antibody bevacizumab has demonstrated a significant clinical benefit in patients with non-squamous cell NSCLC in a randomized phase III trial. The addition of bevacizumab to chemotherapy with paclitaxel plus carboplatin provided a significant survival benefit over chemotherapy alone. Bevacizumab is associated with an increased risk of severe bleeding; thus, patients should be carefully selected for bevacizumab treatment. Hypertension is also seen with bevacizumab but can be managed with antihypertensive agents. Ongoing studies are evaluating bevacizumab in other NSCLC settings and are attempting to identify predictive factors for responses to bevacizumab. Antiangiogenic approaches other than bevacizumab are also being investigated, including several small-molecule tyrosine kinase inhibitors that have demonstrated activity in small studies. In some cases, combination therapy with different targeted agents may provide the most comprehensive treatment approach. In a randomized phase II study, bevacizumab in combination with the epidermal growth factor receptor inhibitor erlotinib demonstrated efficacy similar to chemotherapy plus bevacizumab. Ongoing studies are continuing to investigate new agents and identify the patients most likely to benefit from antiangiogenic therapy." @default.
- W2397805874 created "2016-06-24" @default.
- W2397805874 creator A5008593691 @default.
- W2397805874 creator A5063904421 @default.
- W2397805874 creator A5078389632 @default.
- W2397805874 date "2006-11-01" @default.
- W2397805874 modified "2023-09-23" @default.
- W2397805874 title "Angiogenesis inhibition in the treatment of lung cancer." @default.
- W2397805874 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17143257" @default.
- W2397805874 hasPublicationYear "2006" @default.
- W2397805874 type Work @default.
- W2397805874 sameAs 2397805874 @default.
- W2397805874 citedByCount "3" @default.
- W2397805874 countsByYear W23978058742013 @default.
- W2397805874 crossrefType "journal-article" @default.
- W2397805874 hasAuthorship W2397805874A5008593691 @default.
- W2397805874 hasAuthorship W2397805874A5063904421 @default.
- W2397805874 hasAuthorship W2397805874A5078389632 @default.
- W2397805874 hasConcept C121608353 @default.
- W2397805874 hasConcept C126322002 @default.
- W2397805874 hasConcept C143998085 @default.
- W2397805874 hasConcept C167734588 @default.
- W2397805874 hasConcept C2776256026 @default.
- W2397805874 hasConcept C2776694085 @default.
- W2397805874 hasConcept C2777025900 @default.
- W2397805874 hasConcept C2777292972 @default.
- W2397805874 hasConcept C2777802072 @default.
- W2397805874 hasConcept C2778087573 @default.
- W2397805874 hasConcept C2778239845 @default.
- W2397805874 hasConcept C2779438470 @default.
- W2397805874 hasConcept C2780394083 @default.
- W2397805874 hasConcept C2781451048 @default.
- W2397805874 hasConcept C2909325608 @default.
- W2397805874 hasConcept C71924100 @default.
- W2397805874 hasConcept C98274493 @default.
- W2397805874 hasConceptScore W2397805874C121608353 @default.
- W2397805874 hasConceptScore W2397805874C126322002 @default.
- W2397805874 hasConceptScore W2397805874C143998085 @default.
- W2397805874 hasConceptScore W2397805874C167734588 @default.
- W2397805874 hasConceptScore W2397805874C2776256026 @default.
- W2397805874 hasConceptScore W2397805874C2776694085 @default.
- W2397805874 hasConceptScore W2397805874C2777025900 @default.
- W2397805874 hasConceptScore W2397805874C2777292972 @default.
- W2397805874 hasConceptScore W2397805874C2777802072 @default.
- W2397805874 hasConceptScore W2397805874C2778087573 @default.
- W2397805874 hasConceptScore W2397805874C2778239845 @default.
- W2397805874 hasConceptScore W2397805874C2779438470 @default.
- W2397805874 hasConceptScore W2397805874C2780394083 @default.
- W2397805874 hasConceptScore W2397805874C2781451048 @default.
- W2397805874 hasConceptScore W2397805874C2909325608 @default.
- W2397805874 hasConceptScore W2397805874C71924100 @default.
- W2397805874 hasConceptScore W2397805874C98274493 @default.
- W2397805874 hasIssue "11 Suppl 23" @default.
- W2397805874 hasLocation W23978058741 @default.
- W2397805874 hasOpenAccess W2397805874 @default.
- W2397805874 hasPrimaryLocation W23978058741 @default.
- W2397805874 hasRelatedWork W2016092472 @default.
- W2397805874 hasRelatedWork W2022859640 @default.
- W2397805874 hasRelatedWork W2060263774 @default.
- W2397805874 hasRelatedWork W2061440113 @default.
- W2397805874 hasRelatedWork W2083896010 @default.
- W2397805874 hasRelatedWork W2096734361 @default.
- W2397805874 hasRelatedWork W2122033488 @default.
- W2397805874 hasRelatedWork W2267352845 @default.
- W2397805874 hasRelatedWork W2397805874 @default.
- W2397805874 hasRelatedWork W2802659363 @default.
- W2397805874 hasVolume "4" @default.
- W2397805874 isParatext "false" @default.
- W2397805874 isRetracted "false" @default.
- W2397805874 magId "2397805874" @default.
- W2397805874 workType "article" @default.